Increasing Preference for Monoclonal Antibodies is Reflecting Positively on UK Cancer Monoclonal Antibodies Market

UK cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.2% during the forecast period. The rising preference for monoclonal antibodies is leveraging market growth. Monoclonal antibodies act as one of the potential immunotherapies in the country to identify and attach to particular proteins on the cancer cells surface. It works as immunotherapy in several ways as these therapies may trigger the immune system and support the immune system to attack cancer cells. Additionally, it works to prompt the immune system by binding to proteins on cancer cells, which supports cells of the immune system to find and attack the cancer cells. Some monoclonal antibodies have drugs or radioactive substances bind to them, which allows finding cancer cells and delivers the radioactive substance or drug directly to those cells. It is one of the established targeted therapies for both hematologic malignancies and solid tumors. Some monoclonal antibody drugs that are available with their generic names in the UK include rituximab (Mabthera), trastuzumab (Herceptin), bevacizumab (Avastin), and pertuzumab (Perjeta).

Browse the full report description of "UK Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Type (Naked, Conjugated, and Others), By Application (Breast Cancer, Liver Cancer, Blood Cancer, Brain Cancer, Colorectal Cancer, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/uk-cancer-monoclonal-antibodies-market

Scope of the UK Cancer Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type and Application
• Competitive Landscape- AstraZeneca plc, Pfizer Inc., F- Hoffman La-Roche AG, Novartis AG, and Mylan N.V.

Recent Strategic Initiatives in the UK Cancer Monoclonal Antibodies Market

• In July 2020, AstraZeneca plc signed a global development and commercialization agreement with Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) for DS-1062, a proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate of Daiichi Sankyo’s (ADC) and novel medicine to treat multiple tumor types. It is currently in development to treat multiple tumors that commonly show the cell-surface glycoprotein TROP2. 
• In May 2020, AstraZeneca declared that it will partner with ArcherDX, a genomic analysis company engaged in precision oncology. Under the partnership, AstraZeneca will use ArcherDX personalized cancer monitoring which aims to detect minimal residual disease in patients having early-stage non-small cell lung cancer (NSCLC). This personalized assay will be utilized in the Phase III MERMAID-1 trial of AstraZeneca to assess the outcome of adjuvant treatment with Imfinzi (durvalumab). It is a human monoclonal antibody along with chemotherapy versus chemotherapy alone on disease-free survival. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Cancer Monoclonal Antibodies Market-Segmentation

By Type

• Naked 
• Conjugated
• Others (Bispecific)

By Application

• Breast Cancer
• Liver Cancer
• Blood Cancer
• Brain Cancer
• Colorectal Cancer
• Others

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/uk-cancer-monoclonal-antibodies-market